Previous Close | 1.7100 |
Open | 1.7100 |
Bid | 0.7500 |
Ask | 3.1000 |
Strike | 5.00 |
Expire Date | 2024-10-18 |
Day's Range | 1.7100 - 1.7100 |
Contract Range | N/A |
Volume | |
Open Interest | 75 |
AngioDynamics (ANGO) announces the European CE Mark approval of its AlphaVac F1885 System, which is likely to expand the range of therapy alternatives available to pulmonary embolism patients.
Every investor on earth makes bad calls sometimes. But really big losses can really drag down an overall portfolio. So...
LATHAM, N.Y., May 21, 2024--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced European CE Mark approval of the AlphaVac F1885 System for the non-surgical removal of thrombi or emboli from the pulmonary arteries and for the treatment of pulmonary embolism (PE).